C3b

By Targets:	Amylin Receptor (1) Amyloid-β (1) CGRP Receptor (1) Complement System (8) Endogenous Metabolite (1) Isotope-Labeled Compounds (1) Small Interfering RNA (siRNA) (1) Transmembrane Glycoprotein (1) VEGFR (1) α-synuclein (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (2) Endocrinology (2) Inflammation/Immunology (6) Neurological Disease (2)
Oligonucleotides:	Human Pre-designed siRNA Sets (1) siRNAs (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3252A

Pegcetacoplan acetate 1 Publications Verification	Complement System	Inflammation/Immunology
Pegcetacoplan acetate is a pegylated complement *C3/C3b* inhibitor. Pegcetacoplan acetate acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD) ^[3] .

HY-NP004

Cobra Venom Factor CVF	Complement System	Inflammation/Immunology
Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable *C3/C5* convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.) ^[3].

HY-134222A

N-Acetylserine N-Acetyl-L-serine	Endogenous Metabolite Complement System	Others
N-Acetylserine (N-Acetyl-L-serine) is a complement pathway modulator targeting activated third complement protein (C3b) and an amino-terminal residue (an N-terminal acetylation modification group). N-Acetylserine reacts with the exposed thioester group of *C3b* via its hydroxyl group, thereby blocking the covalent binding of glycerol to this thioester group. N-Acetylserine widely exists in soluble proteins of mammalian cells (accounting for approximately 80% of such proteins). N-Acetylserine has a blocking property that prevents direct Edman sequencing of proteins; deblocking is achievable through trifluoroacetic acid-catalyzed N→O acetyl migration followed by β-elimination. N-Acetylserine is suitable for sequencing of proteins with N-terminal acetylserine modification .

HY-P99905

Efdamrofusp alfa 1 Publications Verification IBI302	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-178284

Factor B-IN-7	Complement System	Inflammation/Immunology
Factor B-IN-7 (Compound (I)) is a selective Factor B inhibitor. Factor B-IN-7 inhibits Factor B-C3b interaction to suppress complement hyperactivation. Factor B-IN-7 is promising for research of paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy, and age-related macular degeneration (AMD) associated with complement-mediated diseases .

HY-P991181

VTX-1218	Transmembrane Glycoprotein	Cancer
VTX-1218 is a VSIG4 inhibitor with human K_d 7.4 nM. VTX-1218 blocks VSIG4 activity, relieves VSIG4-mediated macrophage suppression, repolarizes tumor-associated macrophages and induces T cell activation. VTX-1218 upregulates cytokines and chemokines linked to immune cell recruitment. VTX-1218 can be used for the research of multiple cancer types .

HY-P3252AS

Pegcetacoplan-13C3,15N TFA	Isotope-Labeled Compounds Complement System	Inflammation/Immunology
Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

HY-P991022

Ruxoprubart NM8074	Complement System	Endocrinology
Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces *C3b* deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy ^[3].

HY-RS01743

C3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
C3 Human Pre-designed siRNA Set A contains three designed siRNAs for C3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

C3 Human Pre-designed siRNA Set A C3 Human Pre-designed siRNA Set A

HY-P992456

SAR-443809	Complement System	Cardiovascular Disease Endocrinology
SAR-443809 is a selective alternative complement system inhibitor and monoclonal antibody targeting complement factor Bb. SAR-443809 blocks the cleavage of C3 and factor B by selectively binding to the activated form of factor Bb, with a K_D of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for the research of hematological and renal disorders mediated by abnormal alternative complement pathway .

HY-181040

Factor B-IN-8	Complement System	Inflammation/Immunology
Factor B-IN-8 (Compound (3R ,4R )-15) is a potent, selective and orally active factor B inhibitor with an IC₅₀ of 10.2 nM. Factor B-IN-8 can effectively inhibit the binding of factor B to C3b and the subsequent formation of C3 convertase (C3bBb). Factor B-IN-8 can inhibit the deposition of membrane attack complex (MAC) mediated by alternativepathway with an IC₅₀ of 59.3 nM. Factor B-IN-8 can reduce the cleavage of factor B protein and decrease the deposition of complement C3d in the glomeruli and renal tubules. Factor B-IN-8 can be used for researches of arthritis and paroxysmal nocturnal hemoglobinuria (PNH) .

HY-114613

D-Trp-Aib	Amyloid-β α-synuclein CGRP Receptor Amylin Receptor	Neurological Disease Inflammation/Immunology
D-Trp-Aib is a dipeptide and amyloid-β inhibitor with a K_d of 29.6 nM. D-Trp-Aib triggers formation of non-toxic, non-β-sheet, amorphous amyloid β clusters from misfolded amyloid β monomers and toxic amyloid β oligomers, and reduces toxic amyloid β_1-42 deposits. D-Trp-Aib inhibits amyloid fibril formation of α‑synuclein, IAPP and calcitonin. D-Trp-Aib can be used for the research of Alzheimer's disease .

Cat. No.	Product Name	Type

HY-NP004

Cobra Venom Factor CVF	Biochemical Assay Reagents
Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable *C3/C5* convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.) ^[3].

Cobra Venom Factor

CVF

Biochemical Assay Reagents

Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.) ^[3].

Cat. No.	Product Name	Target	Research Area

HY-P3252A

Pegcetacoplan acetate 1 Publications Verification	Complement System	Inflammation/Immunology
Pegcetacoplan acetate is a pegylated complement *C3/C3b* inhibitor. Pegcetacoplan acetate acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD) ^[3] .

HY-P3252AS

Pegcetacoplan-13C3,15N TFA	Isotope-Labeled Compounds Complement System	Inflammation/Immunology
Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

Cat. No.	Product Name	Target	Research Area	Image

HY-P99905

Efdamrofusp alfa 1 Publications Verification IBI302	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-P991181

VTX-1218	Transmembrane Glycoprotein	Cancer
VTX-1218 is a VSIG4 inhibitor with human K_d 7.4 nM. VTX-1218 blocks VSIG4 activity, relieves VSIG4-mediated macrophage suppression, repolarizes tumor-associated macrophages and induces T cell activation. VTX-1218 upregulates cytokines and chemokines linked to immune cell recruitment. VTX-1218 can be used for the research of multiple cancer types .

HY-P991022

Ruxoprubart NM8074	Complement System	Endocrinology
Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces *C3b* deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy ^[3].

HY-P992456

SAR-443809	Complement System	Cardiovascular Disease Endocrinology
SAR-443809 is a selective alternative complement system inhibitor and monoclonal antibody targeting complement factor Bb. SAR-443809 blocks the cleavage of C3 and factor B by selectively binding to the activated form of factor Bb, with a K_D of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for the research of hematological and renal disorders mediated by abnormal alternative complement pathway .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-134222A

N-Acetylserine N-Acetyl-L-serine	Structural Classification Natural Products Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Complement System
N-Acetylserine (N-Acetyl-L-serine) is a complement pathway modulator targeting activated third complement protein (C3b) and an amino-terminal residue (an N-terminal acetylation modification group). N-Acetylserine reacts with the exposed thioester group of *C3b* via its hydroxyl group, thereby blocking the covalent binding of glycerol to this thioester group. N-Acetylserine widely exists in soluble proteins of mammalian cells (accounting for approximately 80% of such proteins). N-Acetylserine has a blocking property that prevents direct Edman sequencing of proteins; deblocking is achievable through trifluoroacetic acid-catalyzed N→O acetyl migration followed by β-elimination. N-Acetylserine is suitable for sequencing of proteins with N-terminal acetylserine modification .

Species:	Human (4) Bovine (1) Mouse (2)
Tag:	SUMO (1) His (6) Avi (1) Fc (1)
Source:	HEK293 (6) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P704545

	Complement C3 Protein, Human (HEK293, hFc) Complement C3; HSE-MSF; C3; CPAMD1; AHUS5; ARMD9; ASP; C3a; C3b; HEL-S-62p	Human	HEK293
	Complement C3/C3a proteins play a key role in initiating the complement system through processing by C3 convertase in the classical and alternative pathways. Upon activation, C3b covalently binds to the surface, while C3a (anaphylatoxin produced by proteolysis of C3) mediates local inflammation. Complement C3 Protein, Human (HEK293, hFc) is the recombinant human-derived Complement C3 protein, expressed by HEK293, with C-hFc labeled tag.

HY-P705136

	Complement C3 Protein, Human (Biotinylated, HEK293, His-Avi) Complement C3; HSE-MSF; C3; CPAMD1; AHUS5; ARMD9; ASP; C3a; C3b; HEL-S-62p	Human	HEK293

HY-P78247

	Complement C3 Protein, Mouse (HEK293, His) Complement C3; HSE-MSF; C3; CPAMD1; AHUS5; ARMD9; ASP; C3a; C3b; HEL-S-62p	Mouse	HEK293
	Complement C3 protein activates the complement system, playing a central role in both classical and alternative pathways. C3b binds covalently to cell surface carbohydrates or immune aggregates, while C3a acts as an inflammatory mediator, inducing neutrophil chemoattraction and promoting smooth muscle contraction, increased vascular permeability, and histamine release. The shorter isoform of C3a stimulates B-cells. Complement C3 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Complement C3 protein, expressed by HEK293 , with C-His labeled tag.

HY-P702819

	Complement C3 Protein, Human (HEK293, His) Complement C3; HSE-MSF; C3; CPAMD1; AHUS5; ARMD9; ASP; C3a; C3b; HEL-S-62p	Human	HEK293
	Complement C3 protein activates the complement system, playing a central role in both classical and alternative pathways. C3b binds covalently to cell surface carbohydrates or immune aggregates, while C3a acts as an inflammatory mediator, inducing neutrophil chemoattraction and promoting smooth muscle contraction, increased vascular permeability, and histamine release. The shorter isoform of C3a stimulates B-cells. Complement C3 Protein, Human (HEK293, His) is the recombinant mouse-derived Complement C3 protein, expressed by HEK293 , with C-10*His labeled tag.

HY-P71552

	Complement C3a Protein, Bovine (His-SUMO) C3Complement C3; Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2]	Bovine	E. coli
	Complement C3/C3a proteins play a key role in initiating the complement system, serving as substrates for C3 convertase in both the classical and alternative pathways. Upon activation, C3 undergoes proteolytic cleavage, yielding C3b, which is covalently bound to surface or immune aggregates. Complement C3a Protein, Bovine (His-SUMO) is the recombinant bovine-derived Complement C3/C3a protein, expressed by E. coli , with N-His, N-SUMO labeled tag.

HY-P703770

	Complement factor I Protein, Mouse (HEK293, His) Complement factor I; C3b/C4B inactivator; Cfi	Mouse	HEK293
	Complement factor I Protein, Mouse (HEK293, His) is the recombinant mouse-derived Complement factor I protein, expressed by HEK293, with C-His tag.

HY-P703793

	Complement factor I Protein, Human (HEK293, His) Complement factor I; C3b/C4B inactivator; CFI	Human	HEK293
	Complement factor I Protein, Human (HEK293, His) is the recombinant human-derived Complement factor I protein, expressed by HEK293, with C-His tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-P3252AS

Pegcetacoplan-13C3,15N TFA
Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

Pegcetacoplan-13C3,15N TFA

Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

Host:	Mouse (5) Rabbit (2)
Reactivity:	Human (7)
Application:	IHC-P (7) ICC/IF (3) WB (3) FC (2) ELISA (3)
Isotype:	IgG (2) IgG1 (3) IgG2b (2)
Conjugation:	Non-conjugated (7) Biotin (1)
Clonality:	Monoclonal (4) Recombinant (1)
Modification:	Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83897

	C3C Antibody (YA3594) ASP; C3a; C3b; AHUS5; ARMD9; CPAMD1; HEL-S-62p	WB, IHC-P, ICC/IF, FC, ELISA	Human
	C3C Antibody (YA3594) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to C3C.

HY-P83897A

	C3C Antibody (YA3594)(PBS only) ASP; C3a; C3b; AHUS5; ARMD9; CPAMD1; HEL-S-62p	WB, IHC-P, ICC/IF, FC, ELISA	Human
	C3C Antibody (YA3594) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to C3C.

HY-P88426

	CFI Antibody (YA8110) AHUS3; ARMD13; C3b-INA; C3bINA; FI; IF; KAF	IHC-P	Human
	CFI Antibody (YA8110) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CFI.

HY-P88426A

	CFI Antibody (YA8110)(PBS only) AHUS3; ARMD13; C3b-INA; C3bINA; FI; IF; KAF	IHC-P	Human
	CFI Antibody (YA8110) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CFI.

HY-P81583

	CD35 Antibody (YA1328) C3bR,Complement receptor type 1,C3b/C4b receptor,CD35	IHC-P	Human
	CD35 Antibody (YA1328) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD35.

HY-P81583A

	CD35 Antibody (YA1328)(PBS only) C3bR,Complement receptor type 1,C3b/C4b receptor,CD35	IHC-P	Human
	CD35 Antibody (YA1328) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD35.

HY-P85894

	CD35 Antibody (YA5586) C3 binding protein; C3b/C4b receptor; C3bR; C4BR; CD 35; CD35; CD35 antigen; complement component; 3b/4b; receptor 1; Knops blood group; complement component; 3b/4b; receptor 1 including Knops blood group system; Complement component receptor 1; Complement receptor 1; Complement receptor type 1; CR 1; CR1; CR1_HUMAN; KN; Knops blood group antigen	IHC-P, WB, ICC/IF, ELISA	Human
	CD35 Antibody (YA5586) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD35.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RS01743

C3 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
C3 Human Pre-designed siRNA Set A contains three designed siRNAs for C3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

C3b

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products